Aurobindo Pharma reports a 10.2% YoY drop in Q1 FY26 PAT due to lower API sales and US market revenue, while its European and growth markets continue to show positive momentum
Aurobindo Pharma on Monday reported a 10 per cent decline in its consolidated net profit to Rs 824 crore for the June quarter, hit by dip in sales in the US and API business vertical. The Hyderabad-based drug maker posted a net profit of Rs 918 crore for the April-June quarter of last fiscal. Revenue from operations increased to Rs 7,868 crore for the June quarter as against Rs 7,567 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing. "We started the year steadily, with our European business maintaining strong growth momentum and our core US business showing resilience despite temporary challenges from destocking and seasonal dynamics," K Nithyananda Reddy, Vice-Chairman and Managing Director of the company said. The company's disciplined execution, operational initiatives, and recent US acquisition strengthens commercial footprint and accelerates growth potential, he added. The board of directors at its meeting held on Monday has approved the payment of ..
Q1 FY26 company results, Aug 4: Marico, Aditya Birla Capital, Ather Energy, Bosch, Delta Corp, Siemens Energy India, Godfrey Phillips, and Inox India will release their April-June quarter report
Trump on Wednesday called India's tariffs on US exports among the highest in the world, with the most strenuous non-monetary trade barriers of any country, in a post on Truth Social